Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers

Crizotinib is an effective drug for patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC), but upon treatment, the tumors inevitably become crizotinib resistant in time. The resistance mechanisms are only partly understood. In this study, we aim to identify gene...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancers (Basel)
Glavni autori: Wei, Jiacong, van der Wekken, Anthonie J., Saber, Ali, Terpstra, Miente M., Schuuring, Ed, Timens, Wim, Hiltermann, T. Jeroen N., Groen, Harry J. M., van den Berg, Anke, Kok, Klaas
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5789360/
https://ncbi.nlm.nih.gov/pubmed/29300322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10010010
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items